SUPERNUS PHARMACEUTICALS, INC. — Director's Dealing 2025

Oct 1, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK: 0001356576
Period of Report: 2025-09-30

Reporting Person: Khattar Jack A. (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-30	Common Stock	M	11510	$25.30	Acquired	1155846	Direct
2025-09-30	Common Stock	S	8588	$48.25	Disposed	1147258	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-09-30	Employee Stock Option (Right to Buy)	$25.30	M	11510	Disposed	2027-02-24	Common Stock (11510)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1005600	Indirect

Footnotes

F1: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.44. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3: The option vests in four equal installments beginning on February 24, 2018